PHAXIAM Therapeutics S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was EUR 1.33 million compared to EUR 31 million a year ago. Net loss was EUR 23.49 million compared to EUR 0.227 million a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 EUR | 0.00% | +1.03% | -35.87% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.87% | 19.13M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- PHAXIAM Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023